Nowadays, various ligands such as peptides, antibodies, antibody fragments, and intact proteins have been effectively employed to functionalize nanodrugs, facilitating targeted delivery to both the BBB and glioma lesions via binding to the TfR. This evidence concerns the gene TFRC and central nervous system cancer.